Nucleic acids encoding and methods of producing fusion proteins

Details Nucleic acids encoding and methods of producing fusion proteins Nucleic acids encoding and methods of producing fusion proteins

2005-10-07

2011-11-08

Gussow, Anne M. (Department: 1643)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S091400, C435S320100, C435S325000

Reexamination Certificate

active

08053569

ABSTRACT:
The invention provides compositions, methods, and kits for increasing transport of agents across the blood brain barrier while allowing their activity once across the barrier to remain substantially intact. The agents are transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems. In some embodiments the agents are therapeutic, diagnostic, or research agents.

REFERENCES:
patent: 4801575 (1989-01-01), Pardridge
patent: 4902505 (1990-02-01), Pardridge et al.
patent: 5154924 (1992-10-01), Friden
patent: 5180820 (1993-01-01), Barde et al.
patent: 5229500 (1993-07-01), Barde et al.
patent: 5438121 (1995-08-01), Barde et al.
patent: 5453361 (1995-09-01), Yancopoulos et al.
patent: 5527288 (1996-06-01), Gross et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: 5656284 (1997-08-01), Balkin
patent: 5672683 (1997-09-01), Friden et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5824782 (1998-10-01), Holzer et al.
patent: 5837231 (1998-11-01), Low et al.
patent: 5848991 (1998-12-01), Gross et al.
patent: 5977307 (1999-11-01), Friden et al.
patent: 5997501 (1999-12-01), Gross et al.
patent: 6041775 (2000-03-01), Century
patent: 6060069 (2000-05-01), Hill et al.
patent: 6284262 (2001-09-01), Place
patent: 6287792 (2001-09-01), Pardridge et al.
patent: 6322808 (2001-11-01), Trautman et al.
patent: 6329508 (2001-12-01), Friden
patent: 6348210 (2002-02-01), Gale
patent: 6361760 (2002-03-01), Murata et al.
patent: 6372250 (2002-04-01), Pardridge
patent: 6375975 (2002-04-01), Modi
patent: 6583272 (2003-06-01), Bailon
patent: 6743427 (2004-06-01), Schenk
patent: 7053202 (2006-05-01), O'Keefe et al.
patent: 7226758 (2007-06-01), Lin et al.
patent: 7294704 (2007-11-01), Simon et al.
patent: 7309687 (2007-12-01), Brines et al.
patent: 7388079 (2008-06-01), Pardridge et al.
patent: 2002/0137684 (2002-09-01), Tchistiakova et al.
patent: 2003/0129186 (2003-07-01), Beliveau et al.
patent: 2003/0165853 (2003-09-01), Pardridge et al.
patent: 2004/0072291 (2004-04-01), Carr et al.
patent: 2004/0101904 (2004-05-01), Pardridge et al.
patent: 2004/0102369 (2004-05-01), Wu et al.
patent: 2005/0142141 (2005-06-01), Pardridge
patent: 2007/0081992 (2007-04-01), Pardridge et al.
patent: 2007/0275882 (2007-11-01), Meijer et al.
patent: 2008/0051564 (2008-02-01), Pardridge et al.
patent: 2009/0068206 (2009-03-01), Pardridge et al.
patent: 2009/0156498 (2009-06-01), Pardridge et al.
patent: 2009/0238789 (2009-09-01), Guyon et al.
patent: 2010/0261647 (2010-10-01), Pardridge et al.
patent: WO 00/15759 (2000-03-01), None
Burgess, W.H., Shaheen, A.M., Ravera, M., Jaye, M., Donohue, P.J., and Winkes, J.A. Possible dissociation of the heparin-binding and mitogenic activities of heparing binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue. Nov. 1990, Jnl Cell Biol vol. 111 pp. 2129-2138.
Coloma, M.J., Lee, H.J., Kurihara, A., Landaw, E.M., Boado, R.J., Morrison, S.L., and Pardridge, W.M. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. 2000, Pharmaceutical Research, vol. 17 No. 3, pp. 266-274.
Gillies, S.D., Lan, Y., Brunkhorst, B., Wong, W-K., Li, Y., and LO. K-M. Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer. 2002, Cancer Immunology and Immunotherapy, vol. 51, pp. 449-460.
Lazar, E., Watanabe, S., Dalton, S. and Sporn, M.B. Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activites. Mar. 1988, Molecular and Cellular Biology, vol. 8 No. 3, pp. 1247-1252.
Lewin, B. Genes IV, 1990, Oxford University Press, p. 810.
Lin, M.C., Wright, D.E., hRuby, V.J., and Rodbell, M. Structure-function relationships in glucagon: properties of highly purified Des-His-, Monoiodo-, and [Des-Asn28,Thr29](homoserine lactone27)-glucagon. 1975 Biochemistry, vol. 14 No. 8, pp. 1559-1563.
Penichet, M.L., Kang, Y-S., Pardridge, W.M., Morrison, S.L., and Shin, S-U. An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain. 1999, Journal of Immunology, vol. 163, pp. 4421-4426.
Rudikoff, S., Giusti, A.M., Cook, W.D., and Scharff, M.D. Single amino acid substitution altering antigen-binding specificity. Mar. 1982, Proceeding of the National Academy of Sciences, vol. 79, pp. 1979-1983.
Schwartz, G.P., Burke, G.T., and Katsoyannis, P.G. A superactive insulin: [B10-aspartic acid]insulin(human). Sep. 1987, Proceedings of the National Academy of Sciences, vol. 84, pp. 6408-6411.
Skolnick, J. and Fetrow, J.S. From genes to protein structure and function: novel applications of computational approaches in the genomic era. 2000, Trends in Biotechnology, vol. 18 No. 1, pp. 34-39.
Wu, D. and Pardridge, W.M. Neuroprotection with noninvasive neurotrophin delivery to the brain. 1999, Proceedings of the National Academy of Sciences, vol. 96, pp. 254-259.
Jefferies, W.A., Brandon, M.R., Williams, A.F., and Hunt, S.V. Analysis of lymphopoietic stem cells with a monoclonal antibody to the rat transferrin receptor. 1985, Immunology, vol. 54, pp. 333-341.
Ibanez, C.F. Structure-function relationships in the neurotrophin family. 1994. Journal of Neurobiology vol. 25 No. 11, pp. 1349-1361.
Chen, G., Dubrawsky, I., Mendez, P., Georgiou, G., and Iverson, B.L. In vitro scanning saturation mutagenesis of all the specificity determining residues in an antibody binding site. Protein Engineering, 1999. vol. 12, pp. 349-356.
Ibanez, C.F., Ilag, L.L, Murray-Rust, J., and Persson, H. An extended surface of binding to Trk tyrosine kinase receptors in NGF and BDNF allows the engineering of a multifunctional pan-neurotrophin. EMBO Journal, 1993. vol. 12, pp. 2281-2293.
Selmayr, M., Strehl, J., Kremer, J.P., Kremmer, E., Doenecke, A., Hallek, M., Menzel, H., Thielemans, K., Thierfelder, S., and Mocikat, R. Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype. Gene Therapy, 1999. vol. 6, pp. 778-784.
Yip, C.C. and Ottensmeyer, P. Three-dimensional structural interactions of insulin and its receptor. Journal of Biological Chemistry, 2003. vol. 278, pp. 27329-27332.
Shin, S., Friden, P., Moran, M., Olson, T., Kang, Y., Pardridge, W.M., and Morrison, S.L. Transferrin-antibody fusion proteins are effective in brain targeting. Proceedings of the National Academy of Sciences, 1995. vol. 92, pp. 2820-2824.
Ai, Yi, et al., 2003. Intraputamenal Infusion of GDNF in Aged Rhesus Monkeys: Distribution and Dopaminergic Effects.The Journal of Comparative Neurology461: 250-261.
Albayrak, S., et al. 1997. Effect of transient focal ischemia on blood-brain barrier permeability in the rat: Correlation to Cell Injury.Acta Neuropathol94: 158-163.
Bachis, Alessia, et al. 2003. Brain-Derived Neurotropic Factor Inhibits Human Immunodeficiency Virus-1/gp 120- Mediated Cerebellar Granule Cell Death by Preventing gp 120 Internalization.The Journal of Neuroscience23 (13): 5712-5722.
Beck, Thomas, et al. 1994. Brain-Derived Neurotropic Factor Protects Against Ischemic Cell Damage in Rat Hippocampus.Journal of Cerebral Blood Flow and Metabolism14: 689-692.
Bifare, Yoeng-Delphine, et al. 2005. Brain-Derived Neurotropic Factor Protects against Multiple Forms of Brain Injury in Bacterial Meningitis.The Journal of Infectious Diseases191: 40-45.
Cheng, Yu, et al. 1997. Marked Age-dependent Neuroprotection by Brain-derived Neurotropic Factor Against Neonatal Hypoxic-Ischemic Brain Injury.Annals of Neurology41 (4): 521-529.
Cheng, Yu Dennis, et al. 2004. Neuroprotection for Ischemic Stroke: Two Decades of Success and Failure.The Journal of the American Society for Experimental Neuro Therapeutics1: 36-45.
Coloma, M. Josephina, et al. 1999. Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor.Pharmaceutical Resea

Affiliated with

Also associated with

Rating

Nucleic acids encoding and methods of producing fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleic acids encoding and methods of producing fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding and methods of producing fusion proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4295940